Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes

Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes - Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001891

Enrollment

Registered

2009-04-15

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

pioglitazone metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients on no other antidiabetic medications (6.0=<HbA1c<10.0%, BMI>=25kg/m2)

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes, patients with severe liver disease, patients with severe renal disease, patients with severe heart disease, patients with history of myocardial infarction within 6 months, patients with severe pancreatic disease, cancer patients, patients with severe diabetic neuropathy, patients with severe diabetic retinopathy, patients with history of lactic acidosis, heavy drinkers, pregnant patients

Design outcomes

Primary

Measure	Time frame
Glucose variability in CGM (area under the glucose curve from pre-meal baseline to baseline, pattern of glucose curve, magnitude of increase in glucose levels and the time to peak glucose levels from baseline after each meal)	—

Secondary

Measure	Time frame
Pre-meal plasma glucose, 2 hour post prandial glucose, side effect, body weight change	—

Countries

Japan

Contacts

Public ContactAya Morimoto

Jikei University School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026